Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 09 May 2023 Results of pooled analysis of LIN-MD-64 & LIN-MD-62 assessing safety and tolerability of linaclotide in pediatric patients with functional constipation, presented at the Digestive Disease Week 2023.
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020
- 28 Oct 2019 According to an Ironwood Pharmaceuticals media release, data from this study will be presented at the merican College of Gastroenterology (ACG) 2019 Annual Scientific Meeting being held in San Antonio, TX, October 25 through October 30, 2019.